Clermont Ferrand cedex 01, France Clinical Trials

A listing of Clermont Ferrand cedex 01, France clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 394 clinical trials
An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma

The overall aim of this project is to improve the outcome of patients diagnosed with ependymoma by improving and harmonising the staging and the standard of care of this patient population and to improve the investigators understanding of the underlying biology thereby informing future treatment. The program will evaluate new …

CHU Clermont- Ferrand - H pital Estaing
 (2.1 away) Contact site
  • 25 views
  • 24 Jan, 2021
  • +61 other locations
Familial Dysglobulinemia

Multiple Myeloma (MM) is a malignant proliferation of monoclonal plasma cells. Myeloma accounts for almost 14% of all hematologic cancers and is essentially incurable. Myeloma commonly evolves from a precursor disease, Monoclonal gammopathy of undetermined significance (MGUS). Despite intensive study, the etiology of MGUS and myeloma are unknown and no …

D partement d'H matologie l'Institut de Canc rologie de la Loire
 (65.2 away) Contact site
  • 25 views
  • 25 Jan, 2021
  • +46 other locations
Efficacy Safety and Tolerability of Atogepant for the Prevention of Chronic Migraine

This study will evaluate the efficacy, safety and tolerability of atogepant in participants with chronic migraine. This study includes a 12-week treatment period.

headache
migraine
CHU Gabriel Montpied
 (1.6 away) Contact site
  • 576 views
  • 02 Jun, 2021
  • +178 other locations
A Phase 3 Multi-Center Randomized Double-Blind Placebo-Controlled Study of Fostamatinib Disodium in the Treatment of wAIHA

The primary objective of this study is to assess the efficacy of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA).

CHU Toulouse, IUCT Oncop le
 (173.5 away) Contact site
  • 113 views
  • 12 Jun, 2021
  • +124 other locations
Study to Determine the Safety Tolerability Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors

The study will determine the recommended Phase 2 dose (RP2D) of ABBV-151 administered as monotherapy and in combination with budigalimab (ABBV-181) as well as to assess the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-151 alone and in combination with budigalimab. The study will consist of 2 phases: dose escalation …

Centre Leon Berard /ID# 218515
 (84.0 away) Contact site
  • 17 views
  • 31 May, 2021
  • +37 other locations
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

This is a randomized, double-blind placebo-controlled multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in patients with primary ITP.

Investigator Site 55
 (121.2 away) Contact site
  • 28 views
  • 13 Jun, 2021
  • +238 other locations
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with …

Centre Hospitalier Lyon Sud
 (83.5 away) Contact site
  • 2 views
  • 05 Jun, 2021
  • +77 other locations
Pembrolizumab Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

This is a randomized, double-blind, study that compares pembrolizumab with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone surgery with curative intent in combination with radiotherapy. The primary hypothesis is that pembrolizumab is superior to placebo in increasing …

mk-3475
pembrolizumab
cancer
adjuvant therapy
CH Lyon Sud Hospices Civils de Lyon ( Site 0350)
 (83.6 away) Contact site
  • 69 views
  • 15 Jun, 2021
  • +141 other locations
Trial of Andexanet in ICH Patients Receiving an Oral FXa Inhibitor

Randomized, controlled clinical trial evaluating the efficacy and safety of andexanet versus usual standard of care in patients with intracranial hemorrhage anticoagulated with a direct oral anticoagulant

CHU Edouard Herriot, Anaesthesia-resuscitation
 (84.0 away) Contact site
  • 19 views
  • 25 Jan, 2021
  • +133 other locations
Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer

CREST: Combination of sasanlimab and alternative BCG Regimens to Evaluate outcomes with Subcutaneous anti-PD-1 Treatment Phase 3 Design with 3 study Arms (A, B and C). Arms A and B consists of two study drugs, PF-06801591 plus BCG. Arm C consists of one study drug, BCG. The study is designed …

Polyclinique de Limoges Site Chenieux
 (87.6 away) Contact site
  • 10 views
  • 09 Jun, 2021
  • +207 other locations